Novartis AG Stock Performance
Novartis AG shares currently trade at $140.79, reflecting a notable pullback over recent periods. Per SID market data, the stock has declined 13.59% over the past month and 10.25% over the trailing three months, erasing much of its earlier momentum. Despite this near-term weakness, NVS maintains a positive 6.99% return over the past twelve months. The stock is trading below both its 50-day moving average of $150.24 and its 200-day moving average of $150.64, according to Massive/Polygon data, signaling sustained downward pressure relative to longer-term trends. The 14-day RSI stands at 57.5, indicating the stock is neither overbought nor oversold at current levels. Novartis carries a beta of 0.438, reflecting substantially lower volatility than the broader market. Average daily trading volume registers at approximately 1.65 million shares, supporting adequate liquidity for institutional positioning. The company holds a market capitalization of approximately $259 billion.
Novartis AG Valuation Analysis
Novartis AG trades at a price-to-earnings ratio of 18.18, according to SID market data, positioning it within a moderate valuation range for the healthcare sector. The company's price-to-book ratio stands at 5.90, per SEC filings, suggesting the market assigns a meaningful premium to Novartis's net asset base, consistent with its portfolio of high-value pharmaceutical assets and intellectual property. The PEG ratio registers at negative 0.79, which reflects atypical growth-adjusted dynamics that complicate traditional growth-at-a-reasonable-price analysis. Novartis offers a dividend yield of approximately 3.31%, providing a notable income component for shareholders and positioning the stock competitively among large-cap pharmaceutical peers. With a market capitalization of approximately $259 billion, Novartis remains one of the largest companies in the global healthcare space. The combination of a mid-teens earnings multiple and above-average yield underscores the stock's current positioning as a value-oriented healthcare holding.
Smart Money Activity for NVS
Novartis AG registers a composite smart money score of 43 out of 100 with a neutral overall signal, per SID market data. Institutional activity represents the strongest component, scoring 21.0 out of 25, indicating robust engagement from large asset managers and fund complexes as documented in 13F institutional filings. Insider activity scores a moderate 12.5 out of 25, suggesting no pronounced directional conviction from company executives and board members based on recent SEC Form 4 filings. Dark pool activity scores 8.5 out of 25, reflecting relatively subdued off-exchange trading interest among institutional participants. Congressional trading activity is minimal at 0.8 out of 25, indicating virtually no disclosed positions or transactions by members of the U.S. Congress. The divergence between strong institutional engagement and weaker scores across other smart money categories creates a mixed picture. The high institutional score suggests that large professional allocators continue to maintain meaningful positions, while the absence of notable insider buying or congressional interest may temper bullish interpretations of the data.
Novartis AG Earnings Outlook
Novartis AG delivered a strong result in its most recently reported quarter, posting actual earnings of $2.41 per share against an analyst estimate of $2.16, representing a positive surprise of $0.25, or approximately 11.6%, according to company earnings reports. Looking ahead, analyst estimates project earnings of $2.10 per share for the quarter reporting on May 1, 2026, followed by $2.13 for the July 16 reporting date and $2.24 for the October 27 quarter, per consensus analyst estimates. This sequential trajectory from $2.10 to $2.24 across upcoming quarters suggests analysts anticipate gradual earnings growth throughout the fiscal period. The most recent beat demonstrated Novartis's capacity to exceed market expectations, though future quarters remain subject to pipeline developments, pricing dynamics, and patent lifecycle considerations. Investors will closely monitor whether the company can sustain the momentum evidenced by its latest earnings surprise across subsequent reporting periods.
Wall Street Analyst Ratings for NVS
Recent Wall Street coverage of Novartis AG reflects a predominantly cautious stance among analysts. Per SID consensus data, three of the five most recent ratings are Hold recommendations, issued by Landesbank Baden-Wuerttemberg on September 23, Berenberg on September 21, and Jefferies on September 18, 2026 — all reiterations of prior Hold ratings. Rothschild & Co Redburn maintained a Sell rating on September 23, representing the most bearish view among recent coverage. Baader Europe/AlphaValue stands as the sole bullish voice, reiterating a Buy rating on September 17. Notably, none of the five recent analyst actions represented rating changes, with each firm maintaining its prior recommendation. This pattern of reiterated ratings suggests a period of analytical consensus stability, with 60% of recent coverage at Hold, 20% at Sell, and 20% at Buy, according to Wall Street analyst reports. The stock's recent 13.59% monthly decline has not prompted any upgrades or downgrades among these covering analysts.
